One fluconazole resistant strain of C. albicans, one strain of C. krusei and one strain of C. glabrata were employed in the present study. The strains were previously considered resistant to fluconazole, according to CLSI criteria. [6] The minimum inhibitory concentration (MIC) for each strain was the following: C. albicans: 64 µg/mL; C. glabrata: 32 µg/mL. C. krusei is intrinsically resistant to fluconazole and MIC is > 64 µg/mL.
Introduction
Several works have pointed photodynamic therapy (PDT) as an alternative treatment for fungal infections. [1] [2] [3] Methylene blue-PDT (MB-PDT) has been associated with increased membrane permeability in Candida yeasts. [1, 4, 5] Among the advantages of antifungal PDT, we can mention the relative selectivity to fungi [4] and the lack of mutagenicity avoiding the selection of resistant strains. [4, 5] Considering the increasing number of Candida isolates resistant to fluconazole and the relative toxicity of this drug as well as analysing the promising results associated to PDT, the present work evaluates the synergic effect of sub-inhibitory concentrations of MB-PDT and fluconazole on Candida albicans, Candida glabrata and Candida krusei. Lyon, et al.: Fluconazole and PDT against resistant Candida strains October-December 2016 MB concentrations of 32 µg/mL or higher. It means that MB-PDT was sub-inhibitory with MB concentrations below 16 µg/mL.
Methylene blue-photodynamic therapy and fluconazole synergism
The MB-PDT was applied to the Candida strains following the protocol described above and employing MB concentrations of 16, 8 and 4 µg/mL. The yeast cells' suspensions were incubated in Sabouraud's dextrose broth with fluconazole in concentrations ranging from 64 to 2 µg/mL for 24 h at 37°C for 24 h. Then, each group was plated in SDA for colony forming counting. Each set of experiments were made in triplicates. For each strain tested, the following controls were included: control 1 -cells did not receive MB-PDT or fluconazole. This control group corresponds to the maximum yeast growth and is considered as 100% of growth; control 2 -cells received only MB-PDT; control 3 -cells received only fluconazole. Figure 1 summarises the treatment and control groups.
The results were submitted to the analysis of variance and to Tukey test. A P < 0.001 was considered as statistically significant.
Results
The analysis of variance demonstrated that the best results were achieved when MB was employed at the concentration of 16 µg/mL. Given that, this concentration of MB was employed for the statistical analysis. Considering the C. albicans strain, the growth in control 2 and control 3 groups was 78.25% and 87.11%, respectively, when compared to control 1 group. These results represent the inhibition of MB-PDT and fluconazole alone against the resistant strains tested and the difference between these two groups and the control group was not considered as statistically significant employing the Tukey's test. Regarding the effect of the synergic treatment MB-PDT (16 µg/mL) plus fluconazole, the growth was 12.93% when compared to control 1 and the difference between the treatment and all the control groups was statistically significant (P < 0.0001), evidencing the effectiveness of the synergic treatment for the C. albicans fluconazole resistant strain.
Regarding the resistant C. glabrata strain, the growth in control 2 and control 3 groups was 52. 07% and 91.85%, respectively, being that the difference between control 1 and control 3 groups was not statistically significant. The treatment group presented growth of 19.04% in comparison with control 1 group and the difference between the treatment and all the control groups was statistically significant (P < 0.0001).
For C. krusei, the growth in control 2 and control 3 groups was 55.78% and 98.02%, respectively, being that the difference between control 1 and control 3 groups was not statistically significant. The treatment group presented growth of 50.90% in comparison with control 1 (P < 0.0001). The difference between the treatment and control 2 group was not statistically significant either, evidencing that the synergism between fluconazole and PDT was not effective against C. krusei.
Discussion
Fluconazole acts by selective inhibition of ergosterol synthesis, which affects membrane permeability. According to Donnelly et al., [5] phenothiazinium photosensitisers can be localised in the membrane of fungal cells. Interestingly, Giroldo et al. [4] demonstrated that MB-PDT increases the cell permeability in C. albicans, which can diminish the resistance of this microorganism to other drugs. In this context, the synergic effect obtained by the combination of MB-PTD and fluconazole could be explained by the action of both agents on the membrane permeability.
Recently, Snell et al. [7] verified that the exposure to miconazole after MB-PDT, enhanced C. albicans killing. These authors tested the same protocol with fluconazole but found that this antifungal drug has neither enhanced C. albicans killing nor induced fungistatic effect. In the present study, however, the combination of MB-PDT and fluconazole showed a synergic interaction. Regarding C. krusei, it is important to notice that the employment of MB-PDT alone achieved approximately the same inhibition effect than the synergic treatment demonstrating that the killing action on C. krusei is due to the PDT action rather than to the combined effect. 
Conclusion
The association of PDT and conventional antifungal therapy with fluconazole against C. albicans and C. glabrata fluconazole-resistant strains demonstrated to be more effective in the inhibition of these microorganisms than both treatments when employed alone.
